论文部分内容阅读
普通肝素作为抗凝药物,在防治血栓性疾病中广泛应用,然而其出血、诱导血小板减少和骨质疏松等副作用限制了其临床应用。近年来。因低分子量肝素(LMWH)的良好抗血栓作用,高生物利用度和较低的。毒副作用而受到人们的关注,逐渐取代肝素用于缺血性卒中,现将有关文献进行综述。 1 LMWH的作用机制 LMWH是普通肝素经化学解聚获得,解聚方法包括化学法、肝素酶分解法及微量照射法,解聚后的相对分子质量平均为4000～5000道尔顿,主要成分是
As an anticoagulant, unfractionated heparin is widely used in the prevention and treatment of thrombotic diseases. However, its side effects such as hemorrhage, induced thrombocytopenia and osteoporosis have limited its clinical application. In recent years. Due to the good antithrombotic effect of low molecular weight heparin (LMWH), high bioavailability and lower. Side effects and people’s attention, and gradually replace heparin for ischemic stroke, the relevant literature is now reviewed. A mechanism of LMWH LMWH is unfractionated heparin obtained by chemical depolymerization, depolymerization methods including chemical methods, heparinase decomposition and micro-irradiation method, depolymerization of the relative molecular mass average of 4000 to 5000 Daltons, the main component Yes